RxDoctor Payments Data

Jessie Zhao, PA

Physician Assistant · Brooklyn, NYNPI 1144991241

Payments from drug & device makers

$6,443in general payments, 2019–2025

Across 231 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$999
  • Amgen$905
  • GSK$734
  • Exact Sciences$598
  • Agios Pharmaceuticals, Inc.$584
  • Gilead$369
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$4056%
  • Food & beverage$6,03894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,443 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$4,252
Medicare patients
19
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl72$39,175
Evenity (2 Syringes)Romosozumab-Aqqg12$29,491
JardianceEmpagliflozin16$17,845
XareltoRivaroxaban11$10,767
Diclofenac Epolamine12$8,385
Combivent RespimatIpratropium/Albuterol Sulfate16$7,533
Breo ElliptaFluticasone/Vilanterol16$6,324
Dexlansoprazole DrDexlansoprazole20$5,789
Diclofenac Sodium22$5,662
Tenofovir Disoproxil Fumarate16$4,101
Halobetasol Propionate52$3,777
Rivastigmine17$2,128
Mometasone Furoate23$1,781
Fluocinonide24$1,562
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEvenity (2 Syringes)$905$29,49112 claims
Boehringer IngelheimJardiance, Combivent Respimat$999$25,37732 claims
Johnson & JohnsonXarelto$19$10,76711 claims
GSKBreo Ellipta$734$6,32416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →